A Case of “Microinvasive Carcinoma of the Bronchus”

2018 ◽  
Vol 11 (2) ◽  
pp. 150-154
Author(s):  
Valeri Y. Andreev ◽  
Danail B. Petrov ◽  
Ivan N. Ivanov ◽  
Yavor Y. Ivanov

Summary Deciding on a treatment approach for early stage lung cancer (0-1) is sometimes difficult because of uncertainties regarding the depth of tumour invasion and its margins. Even with advanced technology, such as endobronchial ultrasound and autofluorescence bronchoscopy, it is often difficult to be precise. In this currently discussed case, treatment of a 61-year-old female patient with early stage IA lung cancer could not proceed for such reasons. Fortunately, timely surgical intervention allowed preservation of lung function and the patient is now under close surveillance.

2004 ◽  
Vol 51 (3,4) ◽  
pp. 234-237 ◽  
Author(s):  
Masaki Hanibuchi ◽  
Seiji Yano ◽  
Nobutaka Edakuni ◽  
Mami Inayama ◽  
Saburo Sone

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e13159-e13159
Author(s):  
Kun Zhang ◽  
Zhoufeng Wang ◽  
Zhe Li ◽  
Jingyi Lu ◽  
Jun Min ◽  
...  

e13159 Background: Lung cancer is one of the most common forms of cancer and is responsible for approximately 1.8 million deaths per year worldwide. The current 5-year survival rate for lung cancer is only 18%; however, this improves to 56% if the cancer is detected early. While low-dose CT scans have shown promise as an early detection method, only 16% of lung cancer is currently detected at an early stage. We therefore set out to develop a non-invasive blood-based screening assay to identify lung cancer at an early stage using ctmDNA (circulating tumor methylated DNA haplotypes). Methods: Blood samples were prospectively collected from two partner hospitals from 325 healthy individuals and 116 individuals diagnosed with lung nodules by low-dose CT scan in EDTA or Streck BCT tubes and immediately separated into plasma. Patients with lung nodules that appeared cancerous then underwent surgical resection, and cancer diagnosis was confirmed via pathology. Patients were matched between healthy and cancer groups by age, sex, and smoking status. Plasma samples were processed using the Singlera Genomics LUNA assay, a targeted bisulfite sequencing method which identifies methylation haplotype patterns related to early-stage lung cancer. 241 samples were used to train a classification model based on pathology results, and 200 samples were used as a test set to validate the model. Results: In the independent test set, the LUNA assay was able to show a sensitivity of 91.9% to detect early-stage lung cancer with a specificity of 93.3% in healthy patients. Even patients with stage Ia lung cancer were readily detected by the LUNA assay (sensitivity of 91.7%). Conclusions: We have shown that ctmDNA can be utilized to non-invasively screen for early-stage lung cancer with high sensitivity and specificity, paving the way for a blood-based lung cancer early screening assay.


2011 ◽  
Vol 9 (3-4) ◽  
pp. 0-0
Author(s):  
Vilma Brazytė ◽  
Narimantas Evaldas Samalavičius ◽  
Renatas Tikuišis ◽  
Povilas Miliauskas

Sigitas Zaremba1, Renatas Aškinis1, Arnoldas Krasauskas1, Saulius Cicėnas1,2 1Vilniaus universiteto Onkologijos institutas, Santariškių g. 1, LT-08660 Vilnius2Vilniaus universiteto Medicinos fakulteto Reabilitacijos, sporto medicinos ir slaugos institutas, Santariškių g. 1, LT-08660 Vilnius El. paštas: [email protected] Įvadas / tikslasPlaučių vėžys yra viena dažniausių onkologinių ligų Lietuvoje, ypač vyrų. Tai solidinis navikas, turintis blogą prognozę daugiausia dėl greito progresavimo. Deja, dauguma atvejų nustatomi vėlyvos stadijos. Sergamumas plaučių vėžiu Lietuvoje yra 38,30 atvejo/100 000 gyventojų, 69,20/100 000 vyrų ir 11,4/100 000 moterų (2010 m). Plaučių vėžio gydymo prognozė gali būti palankesnė, jei nustatomas ir gydomas ankstyvos stadijos plaučių vėžys. Autofluorescencinis (AF) bronchoskopas padeda pamatyti normalioje šviesoje nematomus bronchų gleivinės pokyčius. Šis metodas pasižymi didesniu tyrimo jautrumu, bet mažesniu specifiškumu. Darbo tikslas – pasidalyti Vilniaus universiteto Onkologijos instituto patirtimi naudojant autofluorescencinį bronchoskopą, nustatyti tyrimo jautrumą ir specifiškumą diagnozuojant plaučių vėžį. Tyrimo medžiaga ir metodaiNuo 2009 m. rugsėjo 15 d. iki 2011 m. gegužės 25 d. atliktos autofluorescencinės bronchoskopijos 87 ligoniams. Duomenys apžvelgti retrospektyviai. RezultataiAutofluorescencinės bronchoskopijos metodu tirti 87 ligoniai, iš jų 59 sergantys plaučių vėžiu, 5 – stemplės vėžiu, 7 – kitų lokalizacijų navikine patologija ir 16 – nepiktybinėmis ligomis. Nustatėme baltos šviesos bronchoskopijos ir autofluorescencinės bronchoskopijos tyrimo jautrumą – atitinkamai 0,83 ir 0,87. Specifiškumas abiem atvejais buvo vienodas – 0,68. IšvadosAutofluorescencinė bronchoskopija yra saugus, naudingas diagnostikos metodas, kuris padeda vertinti naviko endobronchinį išplitimą planuojant operacijos apimtį. Mūsų nustatytas baltos šviesos bronchoskopijos ir autofluorescencinės šviesos bronchoskopijos tyrimų jautrumas buvo 0,83 ir 0,87, tai iš esmės atitinka kitų autorių duomenis. Autofluorescencinės šviesos bronchoskopijos tyrimas naudingesnis nustatant ankstyvų stadijų plaučių vėžį ar ikivėžines ligas. Reikšminiai žodžiai: autofluorescencinė bronchoskopija, plaučių vėžys. The value of autofluorescence bronchoscopy in the diagnosis of early lung cancer Sigitas Zaremba1, Renatas Aškinis1, Arnoldas Krasauskas1, Saulius Cicėnas1,2 1 Institute of Oncology, Vilnius University, Santariškių Str. 1, LT-08660 Vilnius, Lithuania2 Vilnius University, Faculty of Medicine, Institute of Rehabilitation, Sport Medicine and Nursing, Santariškių Str. 1, LT-08660 Vilnius, Lithuania E-mail: [email protected] Background / objectiveLung cancer is one of the most common oncologic diseases in Lithuania, especially among males. It is a solid tumour with a poor prognosis due to rapid progression. Unfortunately, most cases are diagnosed at an advanced stage. Lung cancer morbidity in Lithuania is 38.3 / 100000 inhabitants (69.2 / 100000 among males and 11.4 / 100000 among females) (2010). The prognosis of lung cancer treatment could be better if it were diagnosed at an early stage of the disease. Autofluorescence bronchoscopy can help to find bronchial mucosa lesions which were not seen with a white light bronchoscope. This method has a higher sensitivity but a lower specificity. The study presents – to share our experience in using autofluorescence bronchoscopy, to evaluate its sensitivity and specificity. MethodsFrom 15 September 2009 till 25 May 2011, there were 87 patients examined with autofluorescence bronchoscopy at the Vilnius University Institute of Oncology. The data were evaluated retrospectively. ResultsWe examined 87 patients by autofluorescence bronchoscopy: 59 with lung cacner, 5 with esophageal cancer, 7 with other malignant diseases, and 16 with benign diseases. White-light and autofluorescence bronchoscopy sensitivity was 0.83 and 0.87, respectively. The specificity was 0.68 in both methods. ConclusionsAutofluorescence bronchoscopy is a safe, useful diagnostic method allowing to evaluate endobronchial tumour spread when planning surgical resection. We found white-light and autofluorescence bronchoscopy sensitivity to be 0.83 and 0.87, respectively, which correlate with data of other authors. Autofluorescence bronchoscopy is preferable when diagnosing early-stage lung cancer or precancerous lesions. Keywords: autofluorescence bronchoscopy, lung cancer.


2021 ◽  
Vol 16 (3) ◽  
pp. S264-S265
Author(s):  
F. Xu ◽  
L. Yang ◽  
C. Liu ◽  
J. Ying ◽  
Y. Wang

Sign in / Sign up

Export Citation Format

Share Document